Demetre Daskalakis Opens Up About New CDC Job and Priorities in the COVID-19 Era

The first time I ever saw Demetre Daskalakis, M.D., M.P.H., was in April 2017, at an afternoon dance party at the AIDS Memorial in downtown New York to end HIV stigma and celebrate the science of U=U (undetectable equals untransmittable.

As I was boogie-oogie-oogie-ing, my friend asked me if I recognized the DJ. I looked over, and in the music booth was a sexy, tattooed, bald, goateed guy in a cut-up T-shirt and baseball cap. It was Dr. D. At the time, he was the deputy commissioner in the Division of Disease Control for the New York City Department of Health and Mental Hygiene, our HIV champion, and, apparently, a rockin’ music mixologist.

Daskalakis is one of the most brilliant and visionary leaders in the HIV field. Under his dynamic leadership, New York City became the first major city to sign on to the empowering message that is U=U.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below